AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32367059 — intervention group
Group type: COMPARATOR
Intervention: DRD1 rs686 G variant (GG homozygosity) in the study group
Number of subjects: 100
Study 32367059 — intervention group
Group type: EXPERIMENTAL
Intervention: HTR2A rs6313 TT homozygotes
Number of subjects: 100
Study 32367059 — intervention group
Group type: EXPERIMENTAL
Intervention: HTR2A rs2770304 TT homozygous cases
Number of subjects: 100
Study 34557465 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on early childhood intervention (ECI) provided to parents (cases)
Number of subjects: 26
Study 34557465 — intervention group
Group type: COMPARATOR
Intervention: No information on early childhood intervention (ECI) provided to parents (controls)
Number of subjects: 26
Study 32178662 — intervention group
Group type: EXPERIMENTAL
Intervention: AOK‐Junior care program
Number of subjects: 63000
Study 32178662 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary preventive measures
Number of subjects: 63000
Study 32178662 — intervention group
Group type: EXPERIMENTAL
Intervention: Health economic evaluation
Number of subjects: 63000
Study 32178662 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative primary data collection
Number of subjects: 63000
Study 32178662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional design
Number of subjects: 63000
Study 32178662 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal section design
Number of subjects: 63000
Study 32178662 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups with parents and pediatricians
Number of subjects: 63000
Study 34595995 — intervention group
Group type: EXPERIMENTAL
Intervention: KBP-5074
Number of subjects: 0
Study 34595995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33032566 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient THA (discharged on the same day as surgery)
Number of subjects: 0
Study 33032566 — intervention group
Group type: COMPARATOR
Intervention: Standard inpatient THA (minimum of one night in hospital)
Number of subjects: 0
Study 33032566 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient THA
Number of subjects: 0
Study 33032566 — intervention group
Group type: COMPARATOR
Intervention: Standard inpatient THA
Number of subjects: 0
Study 36237580 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese and Western medicine
Number of subjects: 45
Study 36237580 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine
Number of subjects: 45
Study 36237580 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine
Number of subjects: 45
Study 33905746 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea Tree Oil (TTO) shampoo
Number of subjects: 40
Study 33905746 — intervention group
Group type: COMPARATOR
Intervention: Regular eyelid shampoo
Number of subjects: 40
Study 32064729 — intervention group
Group type: EXPERIMENTAL
Intervention: MODY (GCK-MODY)
Number of subjects: 448
Study 32064729 — intervention group
Group type: EXPERIMENTAL
Intervention: MODY (HNF-MODY)
Number of subjects: 448
Study 32064729 — intervention group
Group type: COMPARATOR
Intervention: Non-MODY (T2D)
Number of subjects: 448
Study 32064729 — intervention group
Group type: EXPERIMENTAL
Intervention: HNF-MODY
Number of subjects: 448
Study 35486196 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Treatment (CT)
Number of subjects: 55
Study 35486196 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous Treatment (DT)
Number of subjects: 55
Study 32803728 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Pain Management (GPM) program
Number of subjects: 51
Study 32803728 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong opioids in GPM arm
Number of subjects: 51
Study 35276942 — intervention group
Group type: EXPERIMENTAL
Intervention: MIU (drinking water produced from deep sea water)
Number of subjects: 41
Study 35276942 — intervention group
Group type: COMPARATOR
Intervention: Mineral water (control)
Number of subjects: 41
Study 34013966 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent Intervention (MCI)
Number of subjects: 2645
Study 34013966 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 2645
Study 35272176 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg modified release once daily (QD)
Number of subjects: 30
Study 35272176 — intervention group
Group type: COMPARATOR
Intervention: Vildagliptin 50 mg immediate release twice daily (BID)
Number of subjects: 30
Study 35272176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 30
Study 33963366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein under local anaesthesia (LLA)
Number of subjects: 384
Study 33963366 — intervention group
Group type: COMPARATOR
Intervention: Total extraperitoneal repair (TEP) under general anaesthesia
Number of subjects: 384
Study 32860414 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic surgical ablation (SA)
Number of subjects: 120
Study 32860414 — intervention group
Group type: COMPARATOR
Intervention: Catheter ablation (CA)
Number of subjects: 120
Study 35152580 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaoshen acupuncture combined with artificial tears
Number of subjects: 70
Study 35152580 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears alone (0.1% sodium hyaluronate eye drop, 3 times a day)
Number of subjects: 70
Study 33320381 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ticagrelor (LD group, 45 mg twice daily)
Number of subjects: 0
Study 33320381 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose ticagrelor (SD group, 90 mg twice daily)
Number of subjects: 0
Study 35572937 — intervention group
Group type: EXPERIMENTAL
Intervention: miCBT
Number of subjects: 121
Study 35572937 — intervention group
Group type: EXPERIMENTAL
Intervention: RLX
Number of subjects: 121
Study 35572937 — intervention group
Group type: COMPARATOR
Intervention: WLC
Number of subjects: 121
Study 34224266 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 0
Study 34224266 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or standard care not specified)
Number of subjects: 0
Study 35885456 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency WBV (16–26 Hz) associated to ST (G1)
Number of subjects: 51
Study 35885456 — intervention group
Group type: COMPARATOR
Intervention: WBV sham (G2)
Number of subjects: 51
Study 35885456 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control (G3)
Number of subjects: 51
Study 34610135 — intervention group
Group type: COMPARATOR
Intervention: mOPV2
Number of subjects: 621
Study 34610135 — intervention group
Group type: EXPERIMENTAL
Intervention: nOPV2-c1
Number of subjects: 621
Study 34610135 — intervention group
Group type: EXPERIMENTAL
Intervention: nOPV2-c2
Number of subjects: 621
Study 32986828 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 9719
Study 32986828 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity and Asian race
Number of subjects: 9719
Study 32986828 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 9719
Study 32270634 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) at Yingxiang (LI 20) and Yintang (GV 29) 10 min before anesthesia induction until the end of operation.
Number of subjects: 40
Study 32270634 — intervention group
Group type: COMPARATOR
Intervention: Control group received general anesthesia directly.
Number of subjects: 40
Study 35894078 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide + Metformin (L + M)
Number of subjects: 355
Study 35894078 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric banding
Number of subjects: 355
Study 35894078 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 355
Study 35894078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 33047732 — intervention group
Group type: EXPERIMENTAL
Intervention: S-P-BG group (5% STMP, 5% PAA, 0.5 g/L BG)
Number of subjects: 30
Study 33047732 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 30
Study 33047732 — intervention group
Group type: EXPERIMENTAL
Intervention: BG group (0.5 g/L BG)
Number of subjects: 30
Study 33047732 — intervention group
Group type: EXPERIMENTAL
Intervention: S-P-BG group
Number of subjects: 30
Study 33047732 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 33047732 — intervention group
Group type: EXPERIMENTAL
Intervention: BG group
Number of subjects: 30
Study 33338413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 4304
Study 33338413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study 32459375 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose TKIs
Number of subjects: 77
Study 32459375 — intervention group
Group type: COMPARATOR
Intervention: Full-dose TKIs
Number of subjects: 77
Study 33949051 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational movie on chronic pain management (10 minutes duration)
Number of subjects: 381
Study 33949051 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational movie)
Number of subjects: 381
Study 33949051 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational movie on chronic pain management
Number of subjects: 381
Study 32816358 — intervention group
Group type: EXPERIMENTAL
Intervention: Predisaster PTEs
Number of subjects: 0
Study 32816358 — intervention group
Group type: EXPERIMENTAL
Intervention: Models including PTSS
Number of subjects: 0
Study 32816358 — intervention group
Group type: EXPERIMENTAL
Intervention: Models including PD
Number of subjects: 0
Study 32816358 — intervention group
Group type: EXPERIMENTAL
Intervention: Models including all pre- and postdisaster PTEs
Number of subjects: 0
Study 33241721 — intervention group
Group type: EXPERIMENTAL
Intervention: ubrogepant 50 mg
Number of subjects: 1799
Study 33241721 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1799
Study 32100497 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints (Tiantu, Danzhong, Zhongwan, Zusanli, Taichong, Neiguan) plus esomeprazole (20 mg, twice a day) and mosapride (5 mg, three times a day) for 14 days.
Number of subjects: 84
Study 32100497 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with esomeprazole (20 mg, twice a day) and mosapride (5 mg, three times a day) for 14 days.
Number of subjects: 84
Study 33874955 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 185
Study 33874955 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 185
Study 35606561 — intervention group
Group type: EXPERIMENTAL
Intervention: GRAVo score model including race
Number of subjects: 291
Study 35606561 — intervention group
Group type: EXPERIMENTAL
Intervention: GRAVo score model excluding race
Number of subjects: 291
Study 35606561 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both GRAVo score models
Number of subjects: 291
Study 33839013 — intervention group
Group type: EXPERIMENTAL
Intervention: Rh antigen typing using a fully automated system based on hemagglutination
Number of subjects: 3000
Study 35141776 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff Vision colonoscopy (EVC)
Number of subjects: 1178
Study 35141776 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 1178
Study 34536115 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 842
Study 34536115 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 842
Study 35983530 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable salvianolic acid treatment
Number of subjects: 90
Study 35983530 — intervention group
Group type: COMPARATOR
Intervention: Conventional alteplase and butalbital treatment
Number of subjects: 90
Study 33653317 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC with cisplatin
Number of subjects: 50
Study 33653317 — intervention group
Group type: COMPARATOR
Intervention: SOX regime alone (Control)
Number of subjects: 50
Study 32108161 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine irrigation
Number of subjects: 193
Study 32108161 — intervention group
Group type: COMPARATOR
Intervention: Control (no povidone-iodine irrigation)
Number of subjects: 193
Study 36087842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (four times daily over eight weeks)
Number of subjects: 61
Study 36087842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 36087842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 61
Study 32163139 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC) using an automated autoRIC™ cuff on the upper arm inflated to 200 mmHg for 5 min and deflated for 5 min for four cycles
Number of subjects: 100
Study 32163139 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 100
Study 35081366 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial therapy intervention (3 weeks, 45-minute weekly sessions)
Number of subjects: 69
Study 33655978 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture (LA)
Number of subjects: 92
Study 33655978 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture (SLA)
Number of subjects: 92
Study 36018547 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel milk (200 milliliters daily for 2 months)
Number of subjects: 60
Study 36018547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33941940 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative oral dose of 500mg amoxicillin
Number of subjects: 19
Study 33941940 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative oral dose of 400mg metronidazole
Number of subjects: 19
Study 33941940 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (500mg of Amoxicillin BD, 400mg of metronidazole and painkillers postoperatively)
Number of subjects: 19
Study 35414293 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-for-1 price incentive for fruits and vegetables (F&V)
Number of subjects: 0
Study 34390625 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute compression schedule
Number of subjects: 1244
Study 34390625 — intervention group
Group type: COMPARATOR
Intervention: Other compression rates and slopes (not specified)
Number of subjects: 1244
Study 33981141 — intervention group
Group type: EXPERIMENTAL
Intervention: Rengalin (2 tablets 2 times daily for 4 weeks)
Number of subjects: 238
Study 33981141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 tablets 2 times daily for 4 weeks)
Number of subjects: 238
Study 36086686 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen and progesterone sequential therapy combined with Foley balloon treatment
Number of subjects: 86
Study 36086686 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment plan
Number of subjects: 86
Study 33860709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (600 mg)
Number of subjects: 13
Study 33115517 — intervention group
Group type: EXPERIMENTAL
Intervention: PCCs
Number of subjects: 160
Study 33115517 — intervention group
Group type: COMPARATOR
Intervention: PBMNCs
Number of subjects: 160
Study 33115517 — intervention group
Group type: EXPERIMENTAL
Intervention: PBDSCs transplantation
Number of subjects: 160
Study 33353385 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching (OPC)
Number of subjects: 36
Study 32854573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKI)
Number of subjects: 16
Study 32854573 — intervention group
Group type: COMPARATOR
Intervention: Control group (COVID-19 patients without cancer)
Number of subjects: 16
Study 36258248 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (10, 30, 60, or 90 mg)
Number of subjects: 0
Study 36258248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin D3)
Number of subjects: 0
Study 34582477 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg/day for 10 days
Number of subjects: 214
Study 34582477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 34142111 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P17 (100 mg/ml) continued every 2 weeks (Q2W)
Number of subjects: 607
Study 34142111 — intervention group
Group type: COMPARATOR
Intervention: Reference adalimumab continued every 2 weeks (Q2W)
Number of subjects: 607
Study 34142111 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P17 (100 mg/ml) switched from reference adalimumab
Number of subjects: 607
Study 34142111 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P17 continued
Number of subjects: 607
Study 34142111 — intervention group
Group type: COMPARATOR
Intervention: Reference adalimumab continued
Number of subjects: 607
Study 34142111 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P17 switched from reference adalimumab
Number of subjects: 607
Study 34142111 — intervention group
Group type: COMPARATOR
Intervention: CT-P17 and reference adalimumab
Number of subjects: 607
Study 34142111 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint damage progression
Number of subjects: 607
Study 34142111 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean trough serum adalimumab concentrations
Number of subjects: 607
Study 32613664 — intervention group
Group type: EXPERIMENTAL
Intervention: ERL monotherapy (n = 27)
Number of subjects: 53
Study 32613664 — intervention group
Group type: COMPARATOR
Intervention: MIST (n = 26)
Number of subjects: 53
Study 36386549 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based stratified care using Keele's STarT MSK Tool and risk-matched treatments
Number of subjects: 1211
Study 36386549 — intervention group
Group type: COMPARATOR
Intervention: Usual care (advice, education, medication, referrals)
Number of subjects: 1211
Study 36413059 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based mobile application (used for 7 days)
Number of subjects: 105
Study 36413059 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching methods (control group)
Number of subjects: 105
Study 36413059 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based mobile application (experimental group)
Number of subjects: 105
Study 33309516 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Limitation Questionnaire 25‐item version (WLQ‐25)
Number of subjects: 315
Study 33309516 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Work Limitation Questionnaire (after item reduction and response merging)
Number of subjects: 315
Study 32727451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group using the Patient Preferences for Patient Participation (4Ps) tool
Number of subjects: 0
Study 32727451 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35291806 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 71
Study 35291806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood platelet-rich plasma (PRPc)
Number of subjects: 71
Study 35291806 — intervention group
Group type: COMPARATOR
Intervention: PRP
Number of subjects: 71
Study 35291806 — intervention group
Group type: COMPARATOR
Intervention: PRPc
Number of subjects: 71
Study 33977309 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve leaflet fusion length measurement
Number of subjects: 120
Study 33977309 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow asymmetry, circumferential wall shear stress, and presence of vortices
Number of subjects: 120
Study 35835552 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery plus pulmonary rehabilitation
Number of subjects: 374
Study 35835552 — intervention group
Group type: COMPARATOR
Intervention: Enhanced recovery after surgery alone (control)
Number of subjects: 374
Study 33228458 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to enroll in a clinical trial for a COVID-19 vaccine
Number of subjects: 2768
Study 33228458 — intervention group
Group type: COMPARATOR
Intervention: Willingness to agree to a randomized placebo-controlled study
Number of subjects: 2768
Study 33228458 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with willingness to participate
Number of subjects: 2768
Study 33283612 — intervention group
Group type: EXPERIMENTAL
Intervention: FAmily‐CEntered (FACE®) pACP intervention
Number of subjects: 105
Study 33283612 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 33283612 — intervention group
Group type: EXPERIMENTAL
Intervention: Families living with HIV
Number of subjects: 105
Study 36173208 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education + personalised diet guidance + intensive resistance exercise (Group C)
Number of subjects: 78
Study 36173208 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education + personalised diet guidance (Group B)
Number of subjects: 78
Study 36173208 — intervention group
Group type: COMPARATOR
Intervention: Centralised education alone (Group A)
Number of subjects: 78
Study 32517806 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent hypertension control program
Number of subjects: 1584
Study 32517806 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 1584
Study 35641354 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D virtual reality (VR) using a head-mounted display
Number of subjects: 117
Study 35641354 — intervention group
Group type: COMPARATOR
Intervention: 2D virtual reality (VR) on a laptop screen
Number of subjects: 117
Study 33476377 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-Bearing (WB) assessments (squat-bilateral, squat-unilateral, lunge positions)
Number of subjects: 51
Study 33476377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunge position
Number of subjects: 51
Study 33476377 — intervention group
Group type: COMPARATOR
Intervention: Nonweight-bearing (NWB) assessments (hip external rotation [HER], hip extension [HEXT], hip abduction [HAB])
Number of subjects: 51
Study 36376921 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 558
Study 36376921 — intervention group
Group type: COMPARATOR
Intervention: artesunate-amodiaquine (ASAQ)
Number of subjects: 558